LLY

827.01

-2.91%↓

UNH

518.23

+0.96%↑

JNJ

161.86

+0.53%↑

ABBV

201.15

+0.12%↑

NVO

71.79

-2.39%↓

LLY

827.01

-2.91%↓

UNH

518.23

+0.96%↑

JNJ

161.86

+0.53%↑

ABBV

201.15

+0.12%↑

NVO

71.79

-2.39%↓

LLY

827.01

-2.91%↓

UNH

518.23

+0.96%↑

JNJ

161.86

+0.53%↑

ABBV

201.15

+0.12%↑

NVO

71.79

-2.39%↓

LLY

827.01

-2.91%↓

UNH

518.23

+0.96%↑

JNJ

161.86

+0.53%↑

ABBV

201.15

+0.12%↑

NVO

71.79

-2.39%↓

LLY

827.01

-2.91%↓

UNH

518.23

+0.96%↑

JNJ

161.86

+0.53%↑

ABBV

201.15

+0.12%↑

NVO

71.79

-2.39%↓

Search

AstraZeneca PLC ADR

Closed

72.9 0.03

Overview

Share price change

24h

Current

Min

71.79

Max

73.1

Key metrics

By Trading Economics

Income

-162M

1.7B

Sales

1.3B

15B

P/E

Sector Avg

34.387

71.874

EPS

1.045

Dividend yield

2

Profit margin

11.188

Employees

94,300

EBITDA

330M

4.4B

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+25.43% upside

Dividends

By Dow Jones

Dividend yield

Sector Avg

2.00%

3.03%

Market Stats

By TradingEconomics

Market Cap

241B

Previous open

72.87

Previous close

72.9

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

AstraZeneca PLC ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

24 mar 2025, 03:15 UTC

Major Market Movers

Harbour BioMed Shares Soar on News of AstraZeneca Collaboration

17 mar 2025, 07:42 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buys Belgian EsoBiotec for Up to $1 Billion to Boost Cell-Therapy Portfolio

6 lut 2025, 11:07 UTC

Earnings

AstraZeneca Expects Revenue, Earnings Growth Despite Sales Drop in China -- Update

6 lut 2025, 07:27 UTC

Earnings

AstraZeneca Expects Further Sales, Earnings Growth After Results Beat Market Views

17 mar 2025, 14:43 UTC

Market Talk

AstraZeneca's Latest Rare-Disease Drug Results Slightly Disappoint, Barclays Says -- Market Talk

17 mar 2025, 13:55 UTC

Market Talk
Acquisitions, Mergers, Takeovers

AstraZeneca's EsoBiotec Deal Seen as Logical -- Market Talk

17 mar 2025, 07:04 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Transaction Doesn't Affect Fincl Guidance for 2025.

17 mar 2025, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca: Acquisition Expected to Close in 2Q 2025

17 mar 2025, 07:03 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Pay Up to $575M Upon Development, Regulatory Milestones Being Met

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Make Initial Payment of $425M on Deal Closing

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca Buying EsoBiotec for up to $1B

17 mar 2025, 07:01 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy EsoBiotec to Advance Cell Therapy Ambition

17 mar 2025, 07:00 UTC

Acquisitions, Mergers, Takeovers

AstraZeneca to Buy EsoBiotec

28 lut 2025, 12:00 UTC

Top News

Drug Stocks Are the New Safe Bet in a Shaky Market -- Heard on the Street -- WSJ

26 lut 2025, 14:59 UTC

Market Talk

AstraZeneca's Breast-Cancer Drug Results Seen as Positive Surprise -- Market Talk

26 lut 2025, 08:04 UTC

Market Talk
Earnings

AstraZeneca's Cancer Drug Pipeline Could Fuel $80 Billion Sales Target -- Market Talk

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Co. Maintains Its Rights to Roxadustat in U.S. and in All Markets Not Licensed to Astellas >FGEN

20 lut 2025, 11:34 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Upon Closing, AstraZeneca Will Obtain All Rights to Roxadustat in China >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen: Following Close of Transaction, Co. Will Repay Term Loan Facility to Investment Funds Managed by Morgan Stanley Tactical Value >FGEN

20 lut 2025, 11:33 UTC

Acquisitions, Mergers, Takeovers

FibroGen; Will Receive Enterprise Value of $85M Plus FibroGen Net Cash Held in China at Closing, Currently Estimated to Be About $75M >FGEN

20 lut 2025, 11:31 UTC

Acquisitions, Mergers, Takeovers

FibroGen: To Continue to Advance Its Oncology Pipeline, With Initiation of Phase 2 Monotherapy Trial of FG-3246 in Metastatic Castration-Resistant Prostate Cancer in 2Q 2025 >FGEN

20 lut 2025, 11:30 UTC

Acquisitions, Mergers, Takeovers

FibroGen Announces Sale of FibroGen China to AstraZeneca for About $160M

13 lut 2025, 10:49 UTC

Market Talk
Earnings

AstraZeneca Stands Out With Catalyst-Rich, Diversified Pipeline -- Market Talk

7 lut 2025, 10:30 UTC

Top News

The Drug Industry Is Having Its Own DeepSeek Moment -- Heard on the Street -- WSJ

6 lut 2025, 15:18 UTC

Market Talk

U.K. Health System Needs to Improve Investment Environment, AstraZeneca CEO Says -- Market Talk

6 lut 2025, 13:24 UTC

Market Talk

AstraZeneca's Increased R&D Spend Is a Positive -- Market Talk

6 lut 2025, 12:01 UTC

Earnings

Global Stocks in Spotlight: BYD, Kering, Maersk -- WSJ

6 lut 2025, 11:22 UTC

Market Talk
Earnings

AstraZeneca's Sales Beat, Pipeline Outshines Margin Miss -- Market Talk

6 lut 2025, 11:18 UTC

Market Talk
Earnings

AstraZeneca's Outlook Makes Midterm Target Look Achievable -- Market Talk

6 lut 2025, 11:02 UTC

Market Talk
Earnings

AstraZeneca's China Woes Seem Manageable -- Market Talk

Peer Comparison

Price change

AstraZeneca PLC ADR Forecast

Price Target

By TipRanks

25.43% upside

12 Months Forecast

Average 92.93 USD  25.43%

High 97 USD

Low 88 USD

Based on 6 Wall Street analysts offering 12 month price targets forAstraZeneca PLC ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

N/A / 77.08Support & Resistance

Short Term

Very Strong Bearish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

Weak Bullish Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About AstraZeneca PLC ADR

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology. Its marketed products also comprise Vaxzevria, Beyfortus, Synagis, FluMist, Soliris, Ultomiris, Strensiq, Koselugo, and Kanuma for covid-19 and rare disease. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; BenevolentAI for drug discovery for systemic lupus erythematosus; Lunit for developing AI-Powered Digital Pathology Risk Assessment Tools for NSCLC; and Absci Corporation for AI-driven drug discovery against an oncology target. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.